How I treat paediatric relapsed acute myeloid leukaemia

British Journal of Haematology

Volumn 166, Issue 5, 2014, Pages 636-645

  Kaspers, Gertjan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Minimal residual disease; Personalized therapy; Prognosis; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; CASE REPORT; CHILD; FEMALE; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; RECURRENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84906052001     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12947     Document Type: Article

References (63)

1. Abrahamsson, J., Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson, G., Zeller, B., Forestier, E., Heldrup, J., Hasle, H. & Nordic Society for Paediatric Haematology and Oncology (NOPHO) (2007) Improved outcome after relapse in children with acute myeloid leukaemia. British Journal of Haematology, 136, 229-236.
2. Abrahamsson, J., Forestier, E., Heldrup, J., Jahnukainen, K., Jónsson, O.G., Lausen, B., Palle, J., Zeller, B. & Hasle, H. (2011) Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. Journal of Clinical Oncology, 29, 310-315.
3. Aladjidi, N., Auvrignon, A., Leblanc, T., Perel, Y., Bénard, A., Bordigoni, P., Gandemer, V., Thuret, I., Dalle, J.H., Piguet, C., Pautard, B., Baruchel, A., Leverger, G. & French Society of Pediatric Hematology and Immunology (2003) Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. Journal of Clinical Oncology, 21, 4377-4385.
4. Bachas, C., Schuurhuis, G.J., Hollink, I.H., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., Van Den Heuvel-Eibrink, M.M., De Bont, E.S., Reinhardt, D., Creutzig, U., De Haas, V., Assaraf, Y.G., Kaspers, G.J. & Cloos, J. (2010) High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 116, 2752-2758.
5. Bachas, C., Schuurhuis, G.J., Assaraf, Y.G., Kwidama, Z.J., Kelder, A., Wouters, F., Snel, A.N., Kaspers, G.J. & Cloos, J. (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia, 26, 1313-1320.
6. Balgobind, B.V., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvrignon, A., Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle, H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Lo Nigro, L., Morimoto, A., Perot, C., Pieters, R., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Zwaan, C.M. & Van Den Heuvel-Eibrink, M.M. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 114, 2489-2496.
7. Beier, R., Albert, M.H., Bader, P., Borkhardt, A., Creutzig, U., Eyrich, M., Ehlert, K., Gruhn, B., Greil, J., Handgretinger, R., Holter, W., Klingebiel, T., Kremens, B., Lang, P., Mauz-Körholz, C., Meisel, R., Müller, I., Peters, C., Reinhardt, D., Sedlacek, P., Schulz, A., Schuster, F.R., Schrauder, A., Strahm, B., Sykora, K.W., Wössmann, W., Zimmermann, M. & Sauer, M.G. (2013) Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplantation, 48, 651-656.
8. Buaboonnam, J., Cao, X., Pauley, J.L., Pui, C.H., Ribeiro, R.C., Rubnitz, J.E. & Inaba, H. (2013) Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatric Blood & Cancer, 60, 1161-1164.
9. Burnett, A.K., Goldstone, A., Hills, R.K., Milligan, D., Prentice, A., Yin, J., Wheatley, K., Hunter, A. & Russell, N. (2013) Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of Clinical Oncology, 31, 1293-1301.
10. Cloos, J., Goemans, B.F., Hess, C.J., Van Oostveen, J.W., Waisfisz, Q., Corthals, S., De Lange, D., Boeckx, N., Hählen, K., Reinhardt, D., Creutzig, U., Schuurhuis, G.J., Zwaan, Ch.M. & Kaspers, G.J. (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 20, 1217-1220.
11. Coenen, E.A., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvrignon, A., Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle, H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Lo Nigro, L., Morimoto, A., Perot, C., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Pieters, R., Zwaan, C.M. & Van Den Heuvel-Eibrink, M.M. (2011) Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 117, 7102-7111.
12. Cooper, T.M., Franklin, J., Gerbing, R.B., Alonzo, T.A., Hurwitz, C., Raimondi, S.C., Hirsch, B., Smith, F.O., Mathew, P., Arceci, R.J., Feusner, J., Iannone, R., Lavey, R.S., Meshinchi, S. & Gamis, A. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer, 118, 761-769.
13. Creutzig, U., Diekamp, S., Zimmermann, M. & Reinhardt, D. (2007) Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric Blood & Cancer, 48, 651-662.
14. Creutzig, U., Van Den Heuvel-Eibrink, M.M., Gibson, B., Dworzak, M.N., Adachi, S., De Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., Lehrnbecher, T., Leverger, G., Mejstrikova, E., Meshinchi, S., Pession, A., Raimondi, S.C., Sung, L., Stary, J., Zwaan, C.M., Kaspers, G.J., Reinhardt, D. & AML Committee of the International BFM Study Group (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, 120, 3187-3205.
15. Creutzig, U., Zimmermann, M., Bourquin, J.P., Dworzak, M.N., Fleischhack, G., Graf, N., Klingebiel, T., Kremens, B., Lehrnbecher, T., von Neuhoff, C., Ritter, J., Sander, A., Schrauder, A., Von Stackelberg, A., Starý, J. & Reinhardt, D. (2013) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood, 122, 37-43.
16. Creutzig, U., Zimmermann, M., Dowrzak, M., Gibson, B., Tamminga, R., Abrahamsson, J., Ha, S.-Y., Hasle, H., Maschan, A., Bertrand, Y., Leverger, G., Von Neuhoff, C., Razzouk, B., Rizzari, C., Smisek, P., Smith, O.P., Stark, B., Reinhardt, D. & Kaspers, G.J.L. (2014) The prognostic significance of early treatment response in pediatric relapsed AML: results of the international study Relapsed AML 2001/01. Haematologica, doi:10.3324/haematol.2014.104182.
17. Esteve, J., Escoda, L., Martín, G., Rubio, V., Díaz-Mediavilla, J., González, M., Rivas, C., Alvarez, C., González San Miguel, J.D., Brunet, S., Tomás, J.F., Tormo, M., Sayas, M.J., Sánchez Godoy, P., Colomer, D., Bolufer, P., Sanz, M.A. & Spanish Cooperative Group PETHEMA (2007) Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia, 21, 446-452.
18. Gibson, B.E., Webb, D.K., Howman, A.J., De Graaf, S.S., Harrison, C.J., Wheatley, K. & United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group (2011) Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. British Journal of Haematology, 155, 366-376.
19. Ginsberg, J.P., Orudjev, E., Bunin, N., Felix, C.A. & Lange, B.J. (2002) Isolated extramedullary relapse in acute myeloid leukemia: a retrospective analysis. Medical and Pediatric Oncology, 38, 387-390.
20. Goemans, B.F., Zwaan, C.M., Miller, M., Zimmermann, M., Harlow, A., Meshinchi, S., Loonen, A.H., Hählen, K., Reinhardt, D., Creutzig, U., Kaspers, G.J. & Heinrich, M.C. (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia, 19, 1536-1542.
21. Goemans, B.F., Tamminga, R.Y., Corbijn, C.M., Hählen, K. & Kaspers, G.J. (2008) Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica, 93, 1418-1420.
22. Gorman, M.F., Ji, L., Ko, R.H., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N.L., Twist, C.J., Eckroth, E., Sposto, R., Gaynon, P.S. & Loh, M.L. (2010) Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatric Blood & Cancer, 55, 421-429.
23. Grimwade, D., Jovanovic, J.V., Hills, R.K., Nugent, E.A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R.E., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, A.K. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology, 27, 3650-3658.
24. Hasle, H., Abrahamsson, J., Forestier, E., Ha, S.Y., Heldrup, J., Jahnukainen, K., Jónsson, Ó.G., Lausen, B., Palle, J., Zeller, B. & Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood, 120, 978-984.
25. Johnston, D.L., Alonzo, T.A., Gerbing, R.B., Lange, B.J. & Woods, W.G. (2005) Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. Journal of Clinical Oncology, 23, 9172-9178.
26. Kaspers, G.J. (2012) Pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 12, 405-413.
27. Kaspers, G.J. & Zwaan, C.M. (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 92, 1519-1532.
28. Kaspers, G.J., Zimmermann, M., Reinhardt, D., Gibson, B.E., Tamminga, R.Y., Aleinikova, O., Armendariz, H., Dworzak, M., Ha, S.Y., Hasle, H., Hovi, L., Maschan, A., Bertrand, Y., Leverger, G.G., Razzouk, B.I., Rizzari, C., Smisek, P., Smith, O., Stark, B. & Creutzig, U. (2013) Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 31, 599-607.
29. Klein, K. & Kaspers, G.J.L. (2013) A review of liposomal daunorubicin in the treatment of acute leukemia. Oncology & Hematology Review, 9, 142-148.
30. Knops, R.R., Van Dalen, E.C., Mulder, R.L., Leclercq, E., Knijnenburg, S.L., Kaspers, G.J., Pieters, R., Caron, H.N. & Kremer, L.C. (2013) The volume effect in paediatric oncology: a systematic review. Annals of Oncology, 24, 1749-1753.
31. Lee, J.W., Jang, P.S., Chung, N.G., Cho, B. & Kim, H.K. (2013) Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 160, 80-86.
32. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
33. Li, X., Xu, S.N., Qin, D.B., Tan, Y., Gong, Q. & Chen, J.P. (2014) Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Annals of Oncology, 25, 455-461.
34. Loken, M.R., Alonzo, T.A., Pardo, L., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Ho, P.A., Franklin, J., Cooper, T.M., Gamis, A.S. & Meshinchi, S. (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 120, 1581-1588.
35. Manara, E., Bisio, V., Masetti, R., Beqiri, V., Rondelli, R., Menna, G., Micalizzi, C., Santoro, N., Locatelli, F., Basso, G. & Pigazzi, M. (2014) Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia, 28, 1132-1134.
36. Meshinchi, S., Leisenring, W.M., Carpenter, P.A., Woolfrey, A.E., Sievers, E.L., Radich, J.P. & Sanders, J.E. (2003) Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biology of Blood and Marrow Transplantation, 9, 706-713.
37. Molgaard-Hansen, L., Möttönen, M., Glosli, H., Jónmundsson, G.K., Abrahamsson, J., Hasle, H. & Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2011) Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia. British Journal of Haematology, 152, 623-630.
38. Molina, B., Lassaletta, A., Gonzalez-Vicent, M., Andión, M., Diaz, M.A. & Madero, L. (2013) Very late isolated CNS relapse of acute myeloid leukemia. Journal of Pediatric Hematology/oncology, 35, e57-e59.
39. Orgel, E., Zung, L., Ji, L., Finklestein, J., Feusner, J. & Freyer, D.R. (2013) Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatric Blood & Cancer, 60, 1528-1533.
40. Perel, Y., Auvrignon, A., Leblanc, T., Michel, G., Reguerre, Y., Vannier, J.P., Dalle, J.H., Gandemer, V., Schmitt, C., Méchinaud, F., Lejars, O., Piguet, C., Couillaud, G., Pautard, B., Landman-Parker, J., Thuret, I., Aladjidi, N., Baruchel, A., Leverger, G. & French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group (2005) Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia, 19, 2082-2089.
41. Pession, A., Masetti, R., Rizzari, C., Putti, M.C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., Santoro, N., Testi, A.M., Zecca, M., Biondi, A., Pigazzi, M., Rutella, S., Rondelli, R., Basso, G., Locatelli, F. & AIEOP AML Study Group (2013) Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 122, 170-178.
42. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Ho, P.A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N.J., Becton, D., Chang, M., Weinstein, H.J., Hirsch, B., Raimondi, S.C., Heerema, N.A., Woods, W.G., Lange, B.J., Hurwitz, C., Arceci, R.J., Radich, J.P., Bernstein, I.D., Heinrich, M.C. & Meshinchi, S. (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood, 115, 2372-2379.
43. Pui, C.H. & Howard, S.C. (2008) Current management and challenges of malignant disease in the CNS in paediatric leukaemia. The Lancet Oncology, 9, 257-268.
44. Pui, C.H., Dahl, G.V., Kalwinsky, D.K., Look, A.T., Mirro, J., Dodge, R.K. & Simone, J.V. (1985) Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood, 66, 1062-1067.
45. Robak, P. & Robak, T. (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treatment Reviews, 39, 851-861.
46. Rubnitz, J.E. (2012) How I treat pediatric acute myeloid leukemia. Blood, 119, 5980-5988.
47. Rubnitz, J.E., Razzouk, B.I., Lensing, S., Pounds, S., Pui, C.H. & Ribeiro, R.C. (2007) Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 109, 157-163.
48. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet Oncology, 11, 543-552.
49. Sander, A., Zimmermann, M., Dworzak, M., Fleischhack, G., Von Neuhoff, C., Reinhardt, D., Kaspers, G.J. & Creutzig, U. (2010) Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 24, 1422-1428.
50. Schultz, K.R., Carroll, A., Heerema, N.A., Bowman, W.P., Aledo, A., Slayton, W.B., Sather, H., Devidas, M., Zheng, H.W., Davies, S.M., Gaynon, P.S., Trigg, M., Rutledge, R., Jorstad, D., Winick, N., Borowitz, M.J., Hunger, S.P., Carroll, W.L. & Camitta, B. (2014) Long term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. Leukemia, doi: 10.1038/leu.2014.30.
51. Shih, L.Y., Liang, D.C., Huang, C.F., Chang, Y.T., Lai, C.L., Lin, T.H., Yang, C.P., Hung, I.J., Liu, H.C., Jaing, T.H., Wang, L.Y. & Yeh, T.C. (2008) Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia, 22, 303-307.
52. Shimada, A., Taki, T., Tabuchi, K., Tawa, A., Horibe, K., Tsuchida, M., Hanada, R., Tsukimoto, I. & Hayashi, Y. (2006) KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood, 107, 1806-1809.
53. Stahnke, K., Boos, J., Bender-Götze, C., Ritter, J., Zimmermann, M. & Creutzig, U. (1998) Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia, 12, 1534-1538.
54. Temming, P., Qureshi, A., Hardt, J., Leiper, A.D., Levitt, G., Ancliff, P.J. & Webb, D.K. (2011) Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatric Blood & Cancer, 56, 625-630.
55. Terwijn, M., van Putten, W.L., Kelder, A., van der Velden, V.H., Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G.E., Valk, P.J., Preijers, F.W., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.C., Löwenberg, B., Ossenkoppele, G.J. & Schuurhuis, G.J. (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology, 31, 3889-3897.
56. Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Journal of Clinical Oncology, 27, 4007-4013.
57. Van Der Velden, V.H., Van Der Sluijs-Geling, A., Gibson, B.E., Te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., De Graaf, S.S., Van Wering, E.R. & Van Dongen, J.J. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.
58. Walter, R.B., Buckley, S.A., Pagel, J.M., Wood, B.L., Storer, B.E., Sandmaier, B.M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J.P., Estey, E.H. & Appelbaum, F.R. (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood, 122, 1813-1821.
59. Webb, D.K., Wheatley, K., Harrison, G., Stevens, R.F. & Hann, I.M. (1999) Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia, 13, 25-31.
60. Weinstein, H.J., Mayer, R.J., Rosenthal, D.S., Coral, F.S., Camitta, B.M. & Gelber, R.D. (1983) Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood, 62, 315-319.
61. Wells, R.J., Woods, W.G., Buckley, J.D., Odom, L.F., Benjamin, D., Bernstein, I., Betcher, D., Feig, S., Kim, T., Ruymann, F., Smithson, W., Srivastava, A., Tannous, R., Buckley, C.M., Whitt, J.K., Wolff, L. & Lampkin, B.C. (1994) Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. Journal of Clinical Oncology, 12, 2367-2377.
62. Wells, R.J., Adams, M.T., Alonzo, T.A., Arceci, R.J., Buckley, J., Buxton, A.B., Dusenbery, K., Gamis, A., Masterson, M., Vik, T., Warkentin, P., Whitlock, J.A. & Children's Cancer Group Study 2951 (2003) Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Journal of Clinical Oncology, 21, 2940-2947.
63. Wheatley, K. (2002) SAB-a promising new treatment to improve remission rates in AML in the elderly? British Journal of Haematology, 118, 432-433.